« back to reports
Q3 2024
Medtech Public Comp Sheet and Valuation Guide
October 15, 2024
Fill out the form to download a preview of this report. The full report is available through the PitchBook Platform.
Table of contents
Tempus IPO highlights positive outlook for medtech
After facing broader market tumult and divestments, precision medicine company Tempus’ post-IPO success could indicate medtech sector stability to come. Valuation multiples are beginning to stabilize, and VC deals are back on the rise after the post-pandemic lull. Analysts expect strong cash flow and profit growth for the sector in 2025 as market conditions improve.
Our Q3 2024 Medtech Public Comp Sheet and Valuation Guide tracks stock performances, valuations, revenue growth, and EBITDA margins for key publicly traded companies.
Table of contents
| Key takeaways | 2 |
| Stock returns | 4 |
| Valuations | 5 |
| Revenue | 6 |
| EBITDA | 7 |